uploads/2019/03/Graph-31-1.png

Analysts Are Mostly Positive on Viking Therapeutics in March

By

Updated

Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 200.82% for Viking Therapeutics (VKTX) based on the company’s closing price on March 26. Analysts revised downwards the company’s target price twice, first from $29.79 in January to $27.31 in February and then to $25.63 in March. The current consensus analyst recommendation for the stock is “buy.”

Of the nine analysts covering Viking Therapeutics, two are recommending a “strong buy,” six are recommending a “buy,” and one analyst is recommending a “hold.”

On March 26, Viking Therapeutics closed at $8.52, 3.52% higher than its previous closing price, 130.89% higher than its 52-week low of $3.69, and 64.50% lower than its 52-week high of $24.00. The company’s market capitalization is $689.01 million.

Based on its closing price on March 26, Viking Therapeutics has reported returns of -1.16% in the last week, -1.05% in the last month, and 17.03% in the last quarter. The company has reported returns of -53.19% in the last half year, 84.82% in the last year, and 11.37% YTD.

Growth trends

In the fourth quarter, Viking Therapeutics reported non-GAAP EPS of -$0.07, ahead of the consensus estimate by $0.03. According to the company’s investor presentation, Viking Therapeutics is currently involved in two major Phase 2 research programs, one evaluating selective thyroid receptor-β agonist VK2809 in the NASH (nonalcoholic steatohepatitis) indication and the other evaluating non-steroidal SARM (selective androgen receptor modulator) VK5211 in the hip fracture recovery indication.

On September 18, Viking Therapeutics issued a press release announcing positive results from the phase 2 trial evaluating VK2809 in NALFD (non-alcoholic fatty liver disease) patients with high LDL-C (low-density lipoprotein cholesterol) levels. According to the company’s investor presentation, Viking Therapeutics expects to initiate a clinical study to evaluate VK2809 in biopsy-confirmed NASH patients in fiscal 2019.

Additionally, Viking Therapeutics is also involved in evaluating investigational therapy VK0214 in the rare disease X-ALD (X-linked adrenoleukodystrophy) indication.

More From Market Realist